These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 16622292)

  • 1. Central nervous system biogenic amine targets for control of appetite and energy expenditure.
    Nelson DL; Gehlert DR
    Endocrine; 2006 Feb; 29(1):49-60. PubMed ID: 16622292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of appetite suppression: implication for the treatment of obesity.
    Halford JC
    Curr Drug Targets; 2001 Dec; 2(4):353-70. PubMed ID: 11732637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A; Lundsgaard C
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatment of obesity.
    Bray GA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug strategies for the treatment of obesity.
    Alemany M; Remesar X; Fernández-López JA
    IDrugs; 2003 Jun; 6(6):566-72. PubMed ID: 12811679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines.
    Nakagawa T; Ukai K; Ohyama T; Gomita Y; Okamura H
    Exp Anim; 2000 Oct; 49(4):239-49. PubMed ID: 11109549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
    Heal DJ; Aspley S; Prow MR; Jackson HC; Martin KF; Cheetham SC
    Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S18-28; discussion S29. PubMed ID: 9758240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin and norepinephrine reuptake inhibition and eating behavior.
    Hainer V; Kabrnova K; Aldhoon B; Kunesova M; Wagenknecht M
    Ann N Y Acad Sci; 2006 Nov; 1083():252-69. PubMed ID: 17148744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does sibutramine work?
    Lean ME
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S8-11. PubMed ID: 11916106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery and status of sibutramine as an anti-obesity drug.
    Luque CA; Rey JA
    Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibutramine and the sympathetic nervous system in obese humans.
    Haynes WG; Egri Z
    Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.
    Halford JC; Harrold JA; Lawton CL; Blundell JE
    Curr Drug Targets; 2005 Mar; 6(2):201-13. PubMed ID: 15777190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modern medical management of obesity: the role of pharmaceutical intervention.
    Aronne LJ
    J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiobesity therapy: emerging drugs and targets.
    Das SK; Chakrabarti R
    Curr Med Chem; 2006; 13(12):1429-60. PubMed ID: 16719787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W; Goa KL
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.